EA200401123A1 - HALOGENACETAMIDE AND AZID-SUBSTITUTED COMPOUNDS AND METHODS OF THEIR APPLICATION - Google Patents

HALOGENACETAMIDE AND AZID-SUBSTITUTED COMPOUNDS AND METHODS OF THEIR APPLICATION

Info

Publication number
EA200401123A1
EA200401123A1 EA200401123A EA200401123A EA200401123A1 EA 200401123 A1 EA200401123 A1 EA 200401123A1 EA 200401123 A EA200401123 A EA 200401123A EA 200401123 A EA200401123 A EA 200401123A EA 200401123 A1 EA200401123 A1 EA 200401123A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conditions
osteoporosis
treatment
androgen
cancer
Prior art date
Application number
EA200401123A
Other languages
Russian (ru)
Inventor
Джеймс Т. Долтон
Дуэйн Д. Миллер
Original Assignee
Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/084,678 external-priority patent/US20020173495A1/en
Application filed by Юниверсити Оф Теннесси Рисерч Фаундейшн filed Critical Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority claimed from PCT/US2003/003122 external-priority patent/WO2003074471A1/en
Publication of EA200401123A1 publication Critical patent/EA200401123A1/en

Links

Abstract

Настоящее изобретение относится к новому классу агентов-мишеней андрогенового рецептора, (ARTA), которые содержат галогенацетамидную или азидную группу и являются алкилирующими агентами. Эти агенты составляют новый подкласс соединений, а именно селективных модуляторов андрогенового рецептора (SARM), которые отдельно или в композиции являются полезными для а) мужской контрацепции; б) лечения разнообразных гормонзависимых состояний, например состояний, связанных со снижением андрогена при старении мужчин (ADAM), таких как усталость, депрессия, уменьшенное либидо, половая дисфункция, эректильная дисфункция, гипогонадизм, остеопороз, потеря волос, анемия, тучность, саркопения, остеопения, остеопороз, мягкая гиперплазия простаты, изменения в настроении и восприятии и рак простаты; в) лечения состояний, связанных со снижением андрогена у женщин (ADIF), таких как половая дисфункция, уменьшенное половое либидо, гипогонадизм, саркопения, остеопения, остеопороз, изменения в восприятии и настроении, депрессия, анемия, потеря волос, тучность, эндометриоз, рак груди, рак матки и рак яичников; г) лечения и/или профилактики острых и/или хронических состояний атрофии мышц; д) профилактики и/или лечения состояний сухого глаза; е) оральной андрогензамещающей терапии; ж) уменьшения сферы действия, остановки или начала регресса рака простаты и/или з) вызывания апоптоза раковой клетки.Международная заявка была опубликована вместе с отчетом о международном поиске.The present invention relates to a new class of target androgen receptor agents (ARTA), which contain a haloacetamide or azide group and are alkylating agents. These agents constitute a new subclass of compounds, namely, selective androgen receptor modulators (SARM), which, alone or in composition, are useful for a) male contraception; b) treatment of a variety of hormone-dependent conditions, such as conditions associated with androgen decline during male aging (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia , osteoporosis, mild prostatic hyperplasia, changes in mood and perception, and prostate cancer; c) treatment of conditions associated with androgen decline in women (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, changes in perception and mood, depression, anemia, hair loss, obesity, endometriosis, cancer breast, uterine and ovarian cancer; d) treating and / or preventing acute and / or chronic conditions of muscle atrophy; e) prevention and / or treatment of dry eye conditions; e) oral androgen replacement therapy; g) reduce the incidence, stop or start regression of prostate cancer and / or h) induce cancer cell apoptosis. The international application was published along with an international search report.

EA200401123A 2002-02-28 2003-02-24 HALOGENACETAMIDE AND AZID-SUBSTITUTED COMPOUNDS AND METHODS OF THEIR APPLICATION EA200401123A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/084,678 US20020173495A1 (en) 2000-08-24 2002-02-28 Selective androgen receptor modulators and methods of use thereof
PCT/US2003/003122 WO2003074471A1 (en) 2002-02-28 2003-02-24 Haloacetamide and azide substituted compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
EA200401123A1 true EA200401123A1 (en) 2005-08-25

Family

ID=49447260

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401123A EA200401123A1 (en) 2002-02-28 2003-02-24 HALOGENACETAMIDE AND AZID-SUBSTITUTED COMPOUNDS AND METHODS OF THEIR APPLICATION

Country Status (3)

Country Link
KR (1) KR20040105208A (en)
EA (1) EA200401123A1 (en)
TW (1) TW200413282A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes

Also Published As

Publication number Publication date
TW200413282A (en) 2004-08-01
KR20040105208A (en) 2004-12-14

Similar Documents

Publication Publication Date Title
EA200401122A1 (en) POLISHMISSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF THEIR APPLICATION
EA200500022A1 (en) N-MOSTIC SELECTIVE MODULATORS OF ANDROGENIC RECEPTORS AND METHODS OF THEIR APPLICATION
EA200602151A1 (en) METABOLITES OF SELECTIVE MODULATORS OF ANDROGEN RECEPTORS AND METHODS OF THEIR APPLICATION
ATE533494T1 (en) MULTIPLE SUBSTITUTED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF
TW200503711A (en) Methylene-bridged selective androgen receptor modulators and methods of use thereof
TW200502249A (en) Heterocyclic selective androgen receptor modulators and methods of use thereof
TW200420571A (en) Halogenated selective androgen receptor modulators and methods of use thereof
EA200401121A1 (en) IRREVERSIBLE SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR AND METHODS OF THEIR APPLICATION
EA200501761A1 (en) PROTECTIVE FORMS OF SELECTIVE MODULATORS OF ANDROGEN RECEPTORS AND METHODS OF THEIR APPLICATION
CY1123239T1 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING ENDOMETRIAL HYPERPLASIA
EA201990835A2 (en) ANTIPROGESTIN DOSAGE MODES
TNSN07005A1 (en) TETRAPEPTITIIC ANALOGS
EA200300283A1 (en) SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR AND METHODS OF THEIR APPLICATION
WO2004064747A3 (en) Treating androgen deficiency in female (adif)-associated conditions with sarms
EA201001785A1 (en) MODULATORS OF SPHINGOZIN-1-PHOSPHATE RECEPTORS
EA201070725A1 (en) BIS-Pyridylpyridones as antagonists of receptor 1 melaninconcentrating hormone
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
EA200401123A1 (en) HALOGENACETAMIDE AND AZID-SUBSTITUTED COMPOUNDS AND METHODS OF THEIR APPLICATION
EA202193334A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FXR AGONIST AND FIBRATE FOR USE IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE
RU2008101503A (en) METHOD FOR PREPARING CONCRETE MIX
BR0308076A (en) Irreversibly selective selective androgen receptors and their methods of use
PE20081313A1 (en) PYRROLIDINONE ANILINES AS MODULATORS OF PROGESTERONE RECEPTORS
SV2005002128A (en) "NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS" REF. PC32256A
MX2018002510A (en) A pharmaceutical combination for mood disorders.